Figure 4.

Bevacizumab significantly improves antitumor effect of nab-paclitaxel in vivo. (A, B) Mice bearing orthotopic MDA-MB-231-Luc⁺ tumors of 200 to 250 mm³ were treated with one or two cycles of saline, nab-paclitaxel alone (10 mg/kg, qdx5 cycle), bevacizumab alone (4 mg/kg), or both drugs. (C) A similar experiment was performed in mice bearing ∼310 mm³ tumors that were treated with three cycles of nab-paclitaxel and concurrent bevacizumab or with saline control. The results are presented as the mean tumor volume ± SE per group measured at indicated days after treatment.